Physician profile
Daniel Scott Rees
NPI 1780094011
$3,865.03
in general payments reported to CMS, 2019-2025
33 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $66.74 · 2021: $444 · 2022: $920 · 2023: $1,169 · 2024: $638 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,241.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $492.73 | 2019-2025 | Ofev |
| Astrazeneca Pharmaceuticals Lp | $348.47 | 2020-2025 | Fasenra, Imfinzi |
| Regeneron Healthcare Solutions, INC. | $348.24 | 2021-2025 | Dupixent |
| Pfizer INC. | $266.41 | 2021-2025 | |
| Baxter Healthcare | $263.35 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Actelion Pharmaceuticals US, INC. | $178.30 | 2022-2023 | Uptravi, Opsumit |
| United Therapeutics Corporation | $164.96 | 2022-2025 | Tyvaso, Tyvaso |
| Grifols USA, LLC | $158.16 | 2024-2025 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $156.34 | 2022-2025 | Zerbaxa, Recarbrio |
| Abiomed | $154.00 | 2023 | Impella |
| Glaxosmithkline, LLC. | $133.71 | 2021-2023 | Trelegy Ellipta |
| Ucb, INC. | $128.66 | 2022-2024 | Briviact |
| Mallinckrodt Hospital Products INC. | $126.49 | 2020-2022 | |
| Electromed, INC. | $86.99 | 2022-2025 | Smartvest |
| Inogen, INC. | $86.22 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $73.53 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $68.15 | 2019-2023 | Ultomiris, Soliris |
| Mylan Specialty L.P. | $67.60 | 2019-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $64.52 | 2023-2024 | Xarelto |
| Astellas Pharma US INC | $58.71 | 2020-2022 | |
| Coaptech, INC. | $43.88 | 2024 | Puma System |
| Shionogi INC | $42.83 | 2024 | Fetroja |
| Verona Pharma, INC. | $42.72 | 2025 | Ohtuvayre |
| Paratek Pharmaceuticals, INC. | $41.89 | 2023-2025 | Nuzyra |
| La Jolla Pharmaceutical Company | $41.13 | 2024 | Giapreza |
| Vifor Pharma, INC. | $33.45 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $32.00 | 2019 | |
| Cleerly, INC. | $26.90 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Vapotherm INC | $23.62 | 2022 | |
| Chiesi USA, INC. | $20.26 | 2022 | |
| Amgen INC. | $19.36 | 2019 | |
| Liquidia Technologies, INC. | $17.84 | 2025 | Yutrepia |
| Bard Peripheral Vascular, INC. | $14.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.